Learn More
, two errors have been corrected in the online version. 1. The Treatment Objectives and Outcomes section contained an error which has been corrected to read: " Short-term outcomes can be measured biochemically (normalization of serum ALT levels), virologically (absence of HCV RNA from serum by a sensitive PCR based assay), and histologically (>2 point(More)
This practice guideline has been approved by the American Association for the Study of Liver Diseases (AASLD) and endorsed by the Infectious Diseases Society of America, the American College of Gastroen-terology and the National Viral Hepatitis Roundtable. Preamble These recommendations provide a data-supported approach to establishing guidelines. They are(More)
PURPOSE To review information on the use of laboratory tests in screening, diagnosis, and monitoring of acute and chronic hepatic injury. DATA SOURCES AND STUDY SELECTION A MEDLINE search was performed for key words related to hepatic diseases, including acute hepatitis, chronic hepatitis, alcoholic hepatitis, cirrhosis, hepatocellular carcinoma, and(More)
BACKGROUND Tests for hepatitis C antibodies (anti-HCV enzyme immunoassays) are usually described as positive or negative. Several studies, mainly in blood donors, have found that specimens with low signal/cutoff (S/C) ratios are commonly negative when tested with a recombinant immunoblot assay (RIBA) or for HCV RNA. METHODS We retrospectively reviewed 17(More)
Preamble These recommendations provide a data-supported approach to establishing guidelines. They are based on the following: (1) a formal review and analysis of the recently published world literature on the topic (Medline search up to Septem-ber 2008); (2) the American College of Physicians' Manual for Assessing Health Practices and Designing Practice(More)
2444 This Journal feature begins with a case vignette that includes a therapeutic recommendation. A discussion of the clinical problem and the mechanism of benefit of this form of therapy follows. Major clinical studies, the clinical use of this therapy, and potential adverse effects are reviewed. Relevant formal guidelines, if they exist, are presented.(More)
This practice guideline has been approved by the American Association for the Study of Liver Diseases (AASLD) and endorsed by the Infectious Diseases Society of America, the American College of Gastroen-terology and the National Viral Hepatitis Roundtable. Preamble These recommendations provide a data-supported approach to establishing guidelines. They are(More)
OBJECTIVE To develop a natural history model for chronic hepatitis C virus (HCV) infection to determine allocation of compensatory funds to Canadians who acquired HCV through the blood supply from 1986 through 1990. METHODS A Markov cohort simulation model for HCV prognosis was developed, using content experts, published data, posttransfusion look-back(More)
TABLES Table 1. Prevalence of HCV infection in hemodialysis patients from various countries S8 Table 2. Summary Table of baseline characteristics of hemodialysis patients tested for HCV (EIA vs. NAT) S16 Table 3. Summary Table of testing for HCV in hemodialysis patients (EIA vs. NAT) S17 Table 4. Evidence Profile for diagnostic testing for HCV in(More)
Three hundred and fifty-two patients with alcoholic hepatitis were evaluated for protein-calorie malnutrition (PCM). In order to facilitate data analysis of nutritional status, a PCM score was calculated for each patient using eight nutritional parameters. The PCM score correlated significantly with mortality, clinical severity of the liver disease, and(More)